title: Modulation of dysarthropneumophonia by low-frequency STN DBS in advanced Parkinson's disease.
abstract: BACKGROUND
  Parkinsonian dysarthria (as typically characterized by hypophonia, monotony of pitch, and rhythm abnormalities) is often accompanied by gait disturbances. The long-term effect of subthalamic nucleus deep brain stimulation (STN DBS) on dysarthria remains unclear.
  
  
  METHODS
  Given STN DBS's known improvement of gait disorders, we analyzed speech intelligibility and aerodynamic and acoustic parameters in 11 advanced PD patients in three double-blind, randomized conditions: "defined Off," 60 Hz STN DBS and 130 Hz STN DBS.
  
  
  RESULTS
  An improvement in aerodynamic speech parameters during 60 Hz STN DBS was accompanied by significant clinical benefit.
  
  
  CONCLUSIONS
  Chronic treatment with low-frequency STN DBS may have a beneficial impact on dysarthropneumophonia, even in advanced PD patients.
authors.affiliation: Service de neurologie et pathologie du mouvement, Université Lille Nord de France, France. caroline.moreau@chru-lille.fr
authors.forename: Caroline
authors.initials: C
authors.lastname: Moreau
authors.forename: Odile
authors.initials: O
authors.lastname: Pennel-Ployart
authors.forename: Serge
authors.initials: S
authors.lastname: Pinto
authors.forename: Audrey
authors.initials: A
authors.lastname: Plachez
authors.forename: Agnes
authors.initials: A
authors.lastname: Annic
authors.forename: François
authors.initials: F
authors.lastname: Viallet
authors.forename: Alain
authors.initials: A
authors.lastname: Destée
authors.forename: Luc
authors.initials: L
authors.lastname: Defebvre
mesh_terms: D000368:Aged; D046690:Deep Brain Stimulation / Q000379:methods*; D004185:Disability Evaluation; D005260:Female; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000150:complications* / Q000628:therapy; D012720:Severity of Illness Index; D013064:Speech Disorders / Q000209:etiology* / Q000628:therapy*; D020531:Subthalamic Nucleus / Q000502:physiology*; D014832:Voice Disorders / Q000209:etiology* / Q000628:therapy*